Current management of juvenile idiopathic arthritis.

[1]  Bin Huang,et al.  Patterns of clinical remission in select categories of juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[2]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[3]  P. Parren,et al.  Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. , 2005, Arthritis and rheumatism.

[4]  H. Tobi,et al.  Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. , 2005, British journal of clinical pharmacology.

[5]  Richard W. Martin,et al.  Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. , 2005, The Journal of rheumatology.

[6]  H. Kautiainen,et al.  Favourable social functioning and health related quality of life of patients with JIA in early adulthood , 2005, Annals of the rheumatic diseases.

[7]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[8]  F. Behrens,et al.  Leflunomide: long-term clinical experience and new uses , 2005, Expert opinion on pharmacotherapy.

[9]  R. Saurenmann,et al.  Leflunomide or methotrexate for juvenile rheumatoid arthritis. , 2005, The New England journal of medicine.

[10]  P. Woo,et al.  Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[11]  A. Tyndall,et al.  Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis , 2005, Bone Marrow Transplantation.

[12]  G. Panayi.  B cell-directed therapy in rheumatoid arthritis--clinical experience. , 2005, The Journal of rheumatology. Supplement.

[13]  H. Ochs,et al.  Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[15]  Li-Chen Chen,et al.  Sulphasalazine in the treatment of children with chronic arthritis , 2005, Clinical Rheumatology.

[16]  I. Foeldvari,et al.  The German etanercept registry for treatment of juvenile idiopathic arthritis , 2004, Annals of the rheumatic diseases.

[17]  R. Sundel,et al.  Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. , 2004, The Journal of pediatrics.

[18]  E. Giannini,et al.  Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. , 2004, The Journal of rheumatology.

[19]  J. Verbsky,et al.  Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. , 2004, The Journal of rheumatology.

[20]  N. Wulffraat,et al.  Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity , 2004, Annals of the rheumatic diseases.

[21]  C. Dinarello.  Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. , 2004, Current opinion in pharmacology.

[22]  R. Saurenmann,et al.  A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. , 2004, Arthritis and rheumatism.

[23]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[24]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[25]  L. Ou,et al.  Sequential changes to clinical parameters and adhesion molecules following intravenous pulse cyclophosphamide and methylprednisolone treatment of refractory juvenile idiopathic arthritis. , 2004, Clinical and Experimental Rheumatology.

[26]  P. Lipsky,et al.  Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[27]  Larry W. Moreland.  IL-1 TRAP , 2004 .

[28]  M. Hochberg,et al.  Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[29]  L. Klareskog,et al.  Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious , 2003, Arthritis research & therapy.

[30]  E. Keystone,et al.  Role of adalimumab in the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[31]  P. Emery,et al.  Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. , 2003, Clinical and experimental rheumatology.

[32]  A. Martini,et al.  Early predictors of outcome in juvenile idiopathic arthritis. , 2003, Clinical and experimental rheumatology.

[33]  M. Boers.  Understanding the window of opportunity concept in early rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[34]  G. Silverman,et al.  Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. , 2003, Arthritis and rheumatism.

[35]  C. Gabay.  IL-1 trap. Regeneron/Novartis. , 2003, Current opinion in investigational drugs.

[36]  R. Cimaz,et al.  Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. , 2003, The Journal of rheumatology.

[37]  P. Vähäsalo,et al.  Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study , 2003, Annals of the rheumatic diseases.

[38]  D. McCurdy,et al.  Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. , 2003, The Journal of rheumatology.

[39]  R. Płoski,et al.  Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. , 2003, The Journal of rheumatology.

[40]  M. Hall,et al.  Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. , 2002, Rheumatology.

[41]  M. Hall,et al.  Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. , 2002, Rheumatology.

[42]  E. Zeggini,et al.  Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. , 2002, Arthritis and rheumatism.

[43]  M. Cheang,et al.  Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. , 2002, The Journal of rheumatology.

[44]  J. Ilonen,et al.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[45]  J. O'dell,et al.  Treating rheumatoid arthritis early: a window of opportunity? , 2002, Arthritis and rheumatism.

[46]  H. McDowell,et al.  Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma , 2002, Archives of disease in childhood.

[47]  S. Bridges,et al.  Early rheumatoid arthritis: a medical emergency? , 2001, The American journal of medicine.

[48]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[49]  K. Minden,et al.  Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. , 2000, The Journal of rheumatology.

[50]  J. Coste,et al.  Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. , 2000, Arthritis and rheumatism.

[51]  B. Chiang,et al.  Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis. , 2000, Journal of the Formosan Medical Association = Taiwan yi zhi.

[52]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[53]  R. Cimaz,et al.  Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. , 2000, The Journal of rheumatology.

[54]  M. Zak,et al.  Juvenile chronic arthritis into adulthood: a long-term follow-up study. , 2000, Rheumatology.

[55]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.

[56]  A. Martini,et al.  Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. , 1999, Clinical and experimental rheumatology.

[57]  Varbanova Bb,et al.  Sulphasalazine. An alternative drug for second-line treatment of juvenile chronic arthritis. , 1999 .

[58]  A. Zwinderman,et al.  Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. , 1998, Arthritis and rheumatism.

[59]  Bleyer Wa.  Methotrexate induced lymphoma , 1998 .

[60]  C. Wallace,et al.  The use of methotrexate in childhood rheumatic diseases. , 1998, Arthritis and rheumatism.

[61]  M. Suarez‐Almazor,et al.  The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. , 1998, The Journal of rheumatology.

[62]  H. Kautiainen,et al.  Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. , 1997, The Journal of rheumatology.

[63]  G. Keenan,et al.  Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. , 1997, Pediatrics.

[64]  D. Sherry,et al.  Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[65]  E. Haddad,et al.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. , 1996, The Journal of pediatrics.

[66]  A. Martini,et al.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. , 1996, The Journal of pediatrics.

[67]  M. Cohen,et al.  Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. , 1995, The American journal of medicine.

[68]  G. Koren,et al.  Influence of food on the bioavailability of oral methotrexate in children. , 1995, The Journal of rheumatology.

[69]  A. Fasth,et al.  The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. , 1995, The Journal of rheumatology.

[70]  A. Fasth,et al.  The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process. , 1995, The Journal of rheumatology.

[71]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. , 1993, The Journal of clinical investigation.

[72]  A. Martini,et al.  Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. , 1993, The Journal of rheumatology.

[73]  C. Bombardier,et al.  Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. , 1992, The Journal of pediatrics.

[74]  P. Woo,et al.  A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. , 1991, Clinical and experimental rheumatology.

[75]  F. Rampen,et al.  Methotrexate and trimethoprim–sulphamethoxazole—a potentially hazardous combination , 1990, Clinical and experimental dermatology.

[76]  W. Bleyer,et al.  Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. , 1989, Arthritis and rheumatism.

[77]  E. Giannini,et al.  Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients. , 1988, Arthritis and rheumatism.

[78]  Frain Jb.  Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. , 1987 .

[79]  E. Giannini,et al.  Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. , 1986, The New England journal of medicine.

[80]  L. Gutterman,et al.  Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. , 1986, The Journal of rheumatology.